99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.
99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.
复制标题
DOI：
10.3390/cancers5020550
复制
发表时间：
2013-05-15
期刊：
影响因子：
5.2
通讯作者：
Reutelingsperger CP
中科院分区：
文献类型：
--
作者：
Schaper FL;Reutelingsperger CP
目前抗癌治疗的疗效评价是通过解剖成像（例如MRI、CT）进行的。结构变化（如果存在）会在治疗开始后 1-2 个月变得明显。因此，癌症患者面临着接受无效治疗的风险，而临床试验需要很长时间才能证明治疗效果。因此，患者和制药行业都可以从治疗效果的早期评估中获益。提供功能级别而非结构级别信息的诊断方法可以提供解决方案。分子成像领域的最新技术进步使得生物过程的体内成像成为可能。由于大多数抗癌疗法通过诱导细胞凋亡来对抗肿瘤，因此细胞凋亡成像可以提供治疗效果的早期评估。本综述重点介绍使用膜联蛋白 A5 进行细胞凋亡分子成像的原理和临床经验，膜联蛋白 A5 是一种广泛接受的动物模型体外和体内细胞凋亡检测标记物。 99mTc-HYNIC-Annexin A5 与 SPECT 相结合已在临床研究中进行了探讨，以评估治疗开始后 1-4 天内化疗和放疗的疗效。基于膜联蛋白 A5 的细胞凋亡功能成像有望提供个性化医疗方法，目前主要用于基于基因组的医学，适用于所有癌症患者。
Evaluation of efficacy of anti-cancer therapy is currently performed by anatomical imaging (e.g., MRI, CT). Structural changes, if present, become apparent 1–2 months after start of therapy. Cancer patients thus bear the risk to receive an ineffective treatment, whilst clinical trials take a long time to prove therapy response. Both patient and pharmaceutical industry could therefore profit from an early assessment of efficacy of therapy. Diagnostic methods providing information on a functional level, rather than a structural, could present the solution. Recent technological advances in molecular imaging enable in vivo imaging of biological processes. Since most anti-cancer therapies combat tumors by inducing apoptosis, imaging of apoptosis could offer an early assessment of efficacy of therapy. This review focuses on principles of and clinical experience with molecular imaging of apoptosis using Annexin A5, a widely accepted marker for apoptosis detection in vitro and in vivo in animal models. 99mTc-HYNIC-Annexin A5 in combination with SPECT has been probed in clinical studies to assess efficacy of chemo- and radiotherapy within 1–4 days after start of therapy. Annexin A5-based functional imaging of apoptosis shows promise to offer a personalized medicine approach, now primarily used in genome-based medicine, applicable to all cancer patients.